GlassScriptPhysician profile
Vigen Vick Abovian
NPI 1104135391
$2,580.72
in general payments reported to CMS, 2019-2025
17 companies · $591 in 2025
The $591 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $549 · 2020: $118 · 2021: $29.98 · 2022: $130 · 2023: $286 · 2024: $878 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,754.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $671.08 | 2022-2025 | Evenity, Otezla, Repatha |
| Abbvie INC. | $628.20 | 2019-2025 | Vraylar |
| Galderma Laboratories, L.P. | $169.96 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.29 | 2019-2024 | Xifaxan |
| Optinose US, INC. | $126.86 | 2024 | |
| Phathom Pharmaceuticals, INC. | $125.56 | 2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $120.36 | 2025 | Caplyta |
| Lilly USA, LLC | $119.92 | 2025 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $119.83 | 2024 | Airsupra |
| Ardelyx, INC. | $104.54 | 2024 | Ibsrela |
| Boston Scientific Corporation | $97.57 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $40.84 | 2025 | Rexulti |
| Astellas Pharma US INC | $33.49 | 2019 | |
| Merz North America, INC. | $33.47 | 2019 | |
| Amarin Pharma, INC. | $31.72 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $15.45 | 2024 | |
| Horizon Therapeutics Plc | $11.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vigen Abovian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.